Twist Bioscience

Wilsonville, OR · 211,995 · 2044 · General & Administration and Manufacturing · Leased

South San Francisco, CA · 91,791 · 2028 · General & Administration, R&D and Manufacturing · Leased

Brisbane, CA · 24,786 · 2026 · Warehouse facility · Leased

Quincy, MA · 38,853 · 2032 · General & Administration, R&D and Manufacturing · Leased

Guangzhou, China · 9,956 · 2026 · General & Administration, Sales & Marketing and Supply Chain activities · Leased

Carlsbad, CA · 8,772 · 2026 · Sales & Marketing · Leased

Singapore · 1,353 · 2028 · Sales & Marketing · Leased

The Company believes its existing facilities are in good operating condition and are suitable for the conduct of its business.

• Issues relating to the use of AI and machine learning and compliance with evolving regulations and industry standards could adversely affect our business and operating results.
• Adverse global economic conditions and U.S. policy changes could have a negative effect on our business, financial condition and results of operations.
• A significant portion of our sales depends on customers’ budgets that may be subject to significant and unexpected variation, including seasonality.
• We generally do not have long-term contracts with our customers requiring them to purchase any specified quantities from us.
• We depend on one single-source supplier for a critical component for our DNA synthesis process. Although we have a reserve of supplies and alternative suppliers exist, the loss of this supplier or its failure to supply us with the necessary component on a timely basis could cause delays in the future capacity of our DNA synthesis process and adversely affect our business.
• We must continue to secure and maintain sufficient and stable supplies of raw materials. Any shortage of raw materials or materials necessary for our production capabilities may adversely affect our business.
• We depend on the continuing efforts of our senior management team and other key personnel, including our scientific and engineering personnel. If we lose members of our senior management team or other key personnel or are unable to successfully retain, recruit and train qualified researchers, engineering and other personnel, our ability to develop our products could be harmed, and we may be unable to achieve our goals.
• We may be unable to successfully recruit and maintain adequate sales, marketing and other support personnel in order to increase our market share and expand our customer base.
• We may engage in strategic transactions, including acquisitions, collaborations, or investments in other companies or technologies, that could disrupt our business, cause dilution to our stockholders, reduce our financial resources, or prove not to be successful.
• We may not achieve the anticipated benefits from the spin out of our DNA data storage application.
• We may be subject to significant pricing pressures and if we are unable to pass on any cost increase to our customers, our business, financial position and results of operations could be adversely affected.
• We use biological and hazardous materials that require considerable expertise and expense for handling, storage and disposal and may result in claims against us.
• We could develop DNA sequences or engage in other activity that contravenes biosecurity requirements, or regulatory authorities could promulgate more far-reaching biosecurity requirements that our standard business practices cannot accommodate, which could give rise to substantial legal liability, impede our business and damage our reputation.
• Third parties may use our products in ways that could damage our reputation.
• A violation of data privacy or data protection laws could adversely harm our operating results and financial condition, damage our reputation or otherwise materially harm our business.
• Because we are subject to existing and potential additional governmental regulation, the markets for our products may be narrowed.
• Our products could in the future be subject to additional regulation by the FDA or other domestic and international regulatory agencies, which could increase our costs and delay our commercialization efforts, thereby materially and adversely affecting our business and results of operations.
• Certain of our potential customers may require that we become certified under the Clinical Laboratory Improvement Amendments of 1988.
• We currently manufacture all of our products and multiple sub-assemblies at our manufacturing facilities in Wilsonville, Oregon and South San Francisco, California, and if either of these facilities are destroyed or we experience at either of these facilities any manufacturing difficulties, disruptions, or delays, this could limit supply of our products or adversely affect our ability to sell products or conduct our clinical trials, and our business would be adversely impacted
• Natural disasters, public health crises, political crises, severe weather events, and other catastrophic events or other events outside of our control may damage our facilities or the facilities of third parties on which we depend and could impact our ability to sell products.
• We may not be able to scale our manufacturing capacity to meet future demand, which could harm our business.
• Delivery of our products could be delayed or disrupted by factors beyond our control, and we could lose customers as a result.
• We may require additional financing to achieve our goals, and such additional financing may not be available acceptable terms, or at all, which could have an adverse effect on our business.
• As we expand our development and commercialization activities outside of the United States, we will be subject to an increased risk of inadvertently conducting activities in a manner that violates the U.S. Foreign Corrupt Practices Act (the "FCPA") and similar laws. If that occurs, we may be subject to civil or criminal penalties which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.
• We could engage in exporting or related activity that contravenes international trade restraints, or regulatory authorities could promulgate more far-reaching international trade restraints, which could give rise to one or more of substantial legal liability, impediments to our business and reputational damage.
• Doing business internationally creates operational and financial risks for our business.
• Our ability to use our net operating loss carryforwards to offset future taxable income may be subject to certain limitations.
• The enactment of legislation implementing changes in taxation of international business activities, the adoption of other corporate tax reform policies, or changes in tax legislation or policies could impact our future financial position and results of operations.
• Ethical, legal and social concerns surrounding the use of genetic information could reduce demand for our technology.
• Risks related to being a public company
• If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired, which would adversely affect our business.
• The requirements of being a public company may strain our resources and require a substantial amount of management’s attention.
• Risks related to our intellectual property
• Our ability to protect our intellectual property and proprietary technology through patents and other means is uncertain.
• If we are unable to obtain, maintain and enforce intellectual property protection, others may be able to make, use, or sell products and technologies substantially the same as ours, which could adversely affect our ability to compete in the market.
• We may not be able to protect our intellectual property rights throughout the world.
• If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected.
• We may be involved in lawsuits to protect or enforce our patents and proprietary rights, to determine the scope, coverage and validity of others’ proprietary rights, or to defend against third party claims of intellectual property infringement that could require us to spend significant time and money and could prevent us from selling our products or impact our stock price.
• We may not be successful in obtaining or maintaining necessary rights to our products and technologies through acquisitions and in-licenses, and our intellectual property agreements with third parties may involve unfavorable terms or be subject to disagreements over contract interpretation.
• We have not yet registered some of our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business.
• We depend on certain technologies that are licensed to us. We do not control these technologies and any loss of our rights to them could prevent us from selling our products.
• Risks relating to owning our common stock
• We have never paid dividends on our capital stock and we do not intend to pay dividends for the foreseeable future. Consequently, any gains from an investment in our common stock will likely depend on whether the price of our common stock increases.
• Our charter documents and Delaware law could prevent a takeover that stockholders consider favorable and could also reduce the market price of our stock.
• Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees.
• General risk factors
• The market price of our common stock is likely to be volatile and could fluctuate or decline, resulting in a substantial loss of your investment.
• Our quarterly and annual operating results and cash flows have fluctuated in the past and might continue to fluctuate, causing the value of our common stock to decline substantially.
• If securities or industry analysts do not publish research or reports about our business or publish negative reports about our business, our share price and trading volume could decline.
• Our actual operating results may differ significantly from our guidance.
• We have in the past and may in the future be subject to short selling strategies that may drive down the market price of our common stock.
• Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause the stock price of our common stock to decline.
• Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.
• Increasing scrutiny and evolving expectations around corporate responsibility practices, specifically related to environmental, social and governance (“ESG”) matters, from investors, lenders, customers, government regulators and other market participants may impose additional costs and expose us to reputational and other risks.